DK1863476T3 - Kombination af antikolinergika og leukotrienreceptorantagonister til behandling af luftvejssygdomme - Google Patents

Kombination af antikolinergika og leukotrienreceptorantagonister til behandling af luftvejssygdomme Download PDF

Info

Publication number
DK1863476T3
DK1863476T3 DK06723360.1T DK06723360T DK1863476T3 DK 1863476 T3 DK1863476 T3 DK 1863476T3 DK 06723360 T DK06723360 T DK 06723360T DK 1863476 T3 DK1863476 T3 DK 1863476T3
Authority
DK
Denmark
Prior art keywords
use according
copd
glycopyrrolate
medicament
combination
Prior art date
Application number
DK06723360.1T
Other languages
English (en)
Inventor
Joachim Maus
Beatrix Fyrnys
Torsten Hoffmann
Mario Weingart
Istvan Szelenyi
Peter Jürgen Cnota
Ullrich Munzel
Ursula Petzold
Original Assignee
Meda Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co Kg filed Critical Meda Pharma Gmbh & Co Kg
Application granted granted Critical
Publication of DK1863476T3 publication Critical patent/DK1863476T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

1. Kombination af R,R-glycopyrrolat eller fysiologisk acceptable salte deraf og montelukast eller fysiologisk acceptable salte deraf til anvendelse til behandling af luftvejssygdomme, herunder allergisk rhinitis, bronkial astma, KOL eller almindelig forkølelse.
2. Kombination til anvendelse ifølge krav 1, hvor den daglige dosis af leukotri-enhæmmeren er fra 1 til 100 mg, fortrinsvis fra 5 til 20 mg.
3. Kombination til anvendelse ifølge krav 1 eller 2, hvor den daglige dosis af R,R-glycopyrrolat er fra 1 til 500 pg.
4. Kombination til anvendelse ifølge krav 1 eller 2, hvor den daglige dosis af R,R-glycopyrrolat er fra 5 til 100 pg.
5. Lægemiddel til anvendelse til behandling af luftvejssygdomme, herunder allergisk rhinitis, bronkial astma, KOL eller almindelig forkølelse, hvilket lægemiddel indeholder R,R-glycopyrrolat eller fysiologisk acceptable salte deraf og montelukast eller fysiologisk acceptable salte deraf.
6. Lægemiddel til anvendelse ifølge krav 5, hvor de aktive stoffer er tilgængelige færdigblandet i en fast kombination, hvis det er relevant sammen med de sædvanlige excipienser, supplementer og tilsætningsstoffer, i en lægemiddelform, som er egnet til anvendelse ved inhalation.
7. Lægemiddel til anvendelse ifølge krav 5, hvor de aktive stoffer er tilgængelige i separate pakningsenheder, hvorved begge stoffer kan tages fra de separate pakningsenheder på en sådan måde, at de er tilgængelige til samtidig anvendelse ved inhalation.
8. Lægemiddel til anvendelse ifølge krav 7, hvor de aktive stoffer kan anvendes uafhængigt af hinanden.
9. Lægemiddel til anvendelse ifølge et af kravene 6-8, kendetegnet ved, at det er en inhalerbar aerosol med eller uden drivmiddel.
10. Lægemiddel til anvendelse ifølge et af kravene 6-8, kendetegnet ved, at det er et inhalerbart tørt pulver.
11. Lægemiddel til anvendelse ifølge et af kravene 6-8, kendetegnet ved, at det er en inhalerbar suspension eller opløsning.
12. Lægemiddel til anvendelse ifølge et hvilket som helst af kravene 6-11, hvilket lægemiddel forefindes i en inhalator.
13. Anvendelse af R,R-glycopyrrolat eller fysiologisk acceptable salte deraf og montelukast eller fysiologisk acceptable salte deraf til fremstilling af et lægemiddel til behandling af luftvejssygdomme, herunder allergisk rhinitis, bronkial astma, KOL eller almindelig forkølelse, hos pattedyr.
14. Anvendelse ifølge krav 13, kendetegnet ved, at pattedyrene er katte, hunde eller heste.
15. Anvendelse ifølge krav 13, hvor sygdommene er kendetegnet ved en ob-struktiv komponent eller bagvedliggende inflammation som astma og kronisk ob-struktiv lungesygdom (KOL).
DK06723360.1T 2005-03-16 2006-03-10 Kombination af antikolinergika og leukotrienreceptorantagonister til behandling af luftvejssygdomme DK1863476T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66191805P 2005-03-16 2005-03-16
PCT/EP2006/002247 WO2006097250A1 (en) 2005-03-16 2006-03-10 The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases

Publications (1)

Publication Number Publication Date
DK1863476T3 true DK1863476T3 (da) 2016-05-17

Family

ID=36570797

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06723360.1T DK1863476T3 (da) 2005-03-16 2006-03-10 Kombination af antikolinergika og leukotrienreceptorantagonister til behandling af luftvejssygdomme

Country Status (19)

Country Link
US (1) US8268864B2 (da)
EP (1) EP1863476B1 (da)
JP (1) JP4991693B2 (da)
CN (1) CN101128196B (da)
AU (1) AU2006224842B2 (da)
CA (1) CA2595791C (da)
CY (1) CY1117571T1 (da)
DK (1) DK1863476T3 (da)
ES (1) ES2570332T3 (da)
HK (1) HK1114013A1 (da)
HR (1) HRP20160373T1 (da)
HU (1) HUE027076T2 (da)
MX (1) MX2007011273A (da)
NO (1) NO340405B1 (da)
NZ (1) NZ560206A (da)
PL (1) PL1863476T3 (da)
RU (1) RU2420285C2 (da)
SI (1) SI1863476T1 (da)
WO (1) WO2006097250A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
EP1660492B1 (en) * 2003-07-28 2008-08-20 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
AU2008314628B2 (en) * 2007-10-18 2014-03-06 Rose U Topical glycopyrrolate formulations
CA2701956A1 (en) * 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Combination therapy
CA2764867C (en) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
US9378456B2 (en) * 2012-11-19 2016-06-28 Microsoft Technology Licensing, Llc Task completion
CN105026369A (zh) 2013-02-28 2015-11-04 德米拉股份有限公司 格隆铵盐
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
EP2968359B1 (en) * 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
JP2016513681A (ja) 2013-03-14 2016-05-16 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
JP2017505809A (ja) * 2014-01-10 2017-02-23 ディグニティ サイエンシス リミテッド １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
KR20210114962A (ko) * 2019-01-10 2021-09-24 장인 무코케어 파마슈티컬 컴퍼니 리미티드 류코트리엔 수용체 길항제를 함유하는 신규 제제
CA3166799A1 (en) * 2020-02-03 2021-08-12 Vered Rosenberger Topical montelukast formulations
CN115792229B (zh) * 2022-01-28 2024-06-18 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0435038A (ja) * 1990-05-31 1992-02-05 Oki Electric Ind Co Ltd 半導体素子及びその製造方法
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
US6204285B1 (en) 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
DK1371645T3 (da) * 1996-11-11 2013-06-03 Meda Pharma Gmbh & Co Kg Anvendelse af (3S,2'R)-glycopyrronium som lægemiddel
CN1253508A (zh) * 1997-04-30 2000-05-17 沃尼尔－朗伯公司 局部鼻用抗炎组合物
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
AU7455498A (en) * 1998-05-29 1999-12-20 Citizen Watch Co. Ltd. Method of subjecting ink jet printer to preuse treatment
NZ509489A (en) 1998-08-04 2002-10-25 Jago Res A Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil
SK284889B6 (sk) 1998-11-13 2006-02-02 Jago Research Ag Použitie stearátu horečnatého v suchých práškových formuláciách na inhaláciu
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
CA2427583C (en) * 2000-10-31 2008-02-12 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
GB0029903D0 (en) 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
US20040101483A1 (en) 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CN1511042A (zh) 2001-05-25 2004-07-07 治疗阻塞性气道疾病的pde4抑制剂与抗胆碱能剂的组合
ATE347361T1 (de) 2001-05-25 2006-12-15 Boehringer Ingelheim Pharma Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
US20040053902A1 (en) * 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
CA2519679C (en) 2003-03-28 2012-08-28 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
WO2005055999A1 (ja) 2003-12-08 2005-06-23 Nippon Shinyaku Co., Ltd. 抗コリン作用剤
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
NO20075287L (no) 2007-12-05
JP2008533072A (ja) 2008-08-21
HRP20160373T1 (hr) 2016-05-06
MX2007011273A (es) 2007-11-08
EP1863476B1 (en) 2016-02-03
PL1863476T3 (pl) 2016-07-29
ES2570332T3 (es) 2016-05-17
AU2006224842B2 (en) 2011-09-29
NO340405B1 (no) 2017-04-18
CA2595791C (en) 2013-10-08
HK1114013A1 (en) 2008-10-24
RU2420285C2 (ru) 2011-06-10
SI1863476T1 (sl) 2016-05-31
CN101128196B (zh) 2013-01-02
CA2595791A1 (en) 2006-09-21
JP4991693B2 (ja) 2012-08-01
US8268864B2 (en) 2012-09-18
AU2006224842A1 (en) 2006-09-21
EP1863476A1 (en) 2007-12-12
CN101128196A (zh) 2008-02-20
US20060211729A1 (en) 2006-09-21
NZ560206A (en) 2009-09-25
RU2007138270A (ru) 2009-04-27
WO2006097250A1 (en) 2006-09-21
HUE027076T2 (en) 2016-08-29
CY1117571T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
DK1863476T3 (da) Kombination af antikolinergika og leukotrienreceptorantagonister til behandling af luftvejssygdomme
TWI404530B (zh) 包含抗蕈毒鹼劑及β-腎上腺素激動劑之組合
JP4700014B2 (ja) 呼吸器系疾患の治療用の抗コリン作用薬及び４型ホスホジエステラーゼの組合せ剤
US5422097A (en) Combined antiviral and antimediator treatment of common colds
EP1713473B1 (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
RU2379033C2 (ru) Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты
KR20200006630A (ko) 로플루밀라스트 n- 옥사이드의 흡입에 의한 자가면역, 호흡 및 염증성 장애의 치료방법
UA119773C2 (uk) Комбінації тіотропію броміду, формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл)
JP2024500567A (ja) フェキソフェナジンを含む組成物